Publication: Compassionate use of remdesivir in children with COVID-19.
No Thumbnail Available
Identifiers
Date
2020-11-16
Authors
Mendez-Echevarria, Ana
Perez-Martinez, Antonio
Gonzalez-Del-Valle, Luis
Ara, Maria Fatima
Melendo, Susana
Ruiz-de-Valbuena, Marta
Vazquez-Martinez, Jose Luis
Morales-Martinez, Antonio
Remesal, Agustin
Sandor-Bajusz, Kinga Amalia
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children.A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment with RDV in Spain. Eight patients were included in the study, four infants and four older children [median age 5 years old; IQR 4 months-11.6 years old]. Half of them had complex underlying medical conditions, and the rest were mostly infants (3/4). Six out of eight children needed Pediatric Intensive Care Unit Admission. No RDV-related adverse outcomes were observed in our patients. Seven have reached successful clinical outcome, but one patient with serious clinical status died due to complications. However, she received RDV very late after the first COVID-19 symptom.Conclusions: In our cohort, most of the patients achieved successful clinical outcome, without observing adverse events. Clinical trials of RDV therapy for children with COVID-19 are urgently needed, to assess the safety, tolerability, efficacy, and pharmacokinetics of RDV in children, as this could be an effective treatment in severe cases. What is Known: • Remdesivir has not been approved to treat COVID-19 in children under 12 years old, although the drug is currently being prescribed in critically ill children. • Remdesivir has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in paediatric population. What is New: • We report a multicentre cohort of children with confirmed SARS-CoV-2 and severe COVID-19 disease receiving remdesivir during the first month of the pandemic in Spain. • No remdesivir-related adverse outcomes were observed in most of the cases. Seven patients reached successful clinical outcome, and one died due to complications (bacterial sepsis).
Description
MeSH Terms
Adenosine Monophosphate
Adolescent
Alanine
Antiviral Agents
Child
Child, Preschool
Compassionate Use Trials
Critical Illness
Female
Humans
Infant
Male
Severity of Illness Index
Spain
Treatment Outcome
COVID-19 Drug Treatment
Adolescent
Alanine
Antiviral Agents
Child
Child, Preschool
Compassionate Use Trials
Critical Illness
Female
Humans
Infant
Male
Severity of Illness Index
Spain
Treatment Outcome
COVID-19 Drug Treatment
DeCS Terms
SARS-CoV-2
Informe de Investigación
Unidades de Cuidado Intensivo Pediátrico
Farmacocinética
Sepsis
Pandemias
Informe de Investigación
Unidades de Cuidado Intensivo Pediátrico
Farmacocinética
Sepsis
Pandemias
CIE Terms
Keywords
COVID-19, Children, Infant, Remdesivir, SARS-CoV-2
Citation
Méndez-Echevarría A, Pérez-Martínez A, Gonzalez Del Valle L, Ara MF, Melendo S, Ruiz de Valbuena M, et al. Compassionate use of remdesivir in children with COVID-19. Eur J Pediatr. 2021 Apr;180(4):1317-1322